PATENT CLAIM ANALYSIS

Application Number: 16239051
Application Type: Utility
Filing Date: 2019-01
Publication Date: 2019-08
Patent Classification: ["514", "264100"]

Abstract:
The present invention relates to bicyclic heterocycles, and pharmaceutical compositions of the same, that are inhibitors of the FGFR4 enzyme and are useful in the treatment of FGFR4-associated diseases such as cancer.

Claim (Index 44):
The method of  claim 40 , wherein the cancer is bladder cancer.

Metadata:
- Claim Count in Document: 86.0
- Percentile: 99.0
- Lexical Diversity: 1.25
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15047892', '15408001', '15047876', '15047903', '15874299']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8445626900140787
- 35 USC 102 Novelty (BERT): 0.5511593456960061
- Combined Prediction Score: 0.8152223555822714
- Mean Citation Score: 427.961696
- Max Citation Score: 462.39725
- Similarity Product: 249.113924393937

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test